Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL

 
• By Joseph Haas
  
EyeDrops
Aldeyra hopes ongoing trials will provide data finally for FDA approval of reproxalap • Source: Shutterstock

More from Strategy

More from R&D